Qualigen Therapeutics Inc. is a biotechnology company. It is focused on developing products for the treatment and testing of cancer and infectious diseases. The company's product pipeline consist AS1411 and Gold Nanoparticle ALAN, RAS-F3 and STARS(TM) blood cleansing system, which are in clinical stage. Qualigen Therapeutics Inc., formerly known as Ritter Pharmaceuticals Inc., is based in CA, United States.
| Revenue (Most Recent Fiscal Year) | $4.98M |
| Net Income (Most Recent Fiscal Year) | $-6.26M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.33 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.33 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-4.12 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.64M |
| Free Float | 1.61M |
| Market Capitalization | $5.59M |
| Average Volume (Last 20 Days) | 0.02M |
| Beta (Past 60 Months) | 0.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |